Skip to content

The Brain Metabolic Change in Chronic Cancer Pain Patient: FDG PET Image Study

Unknown statusNCT04255628
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Cancer pain deteriorated in quality of life and related with numerous psychosocial problems. Over the one third of cancer patient suffered from moderate to severe cancer pain, even under adequate pain management. The 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images can provide quantitative results in clinical oncology. As a functional neuroimaging, the PET evidently provided anatomical activated regions, size, and spatial extent information. In this study, we use FDG-PET to investigate changes concerning the glucose metabolism in the brain with or without cancer pain. Therefore, we may provide useful information to treatment target in cancer pain patients.

Study details

Official title
The Brain Metabolic Change in Chronic Cancer Pain Patient: FDG PET Image Study
Conditions
Interventions
  • Diagnostic test: FDG PET
Sponsor
National Taiwan University Hospital
Start date
2020-03-02
Primary completion
2022-03-28
Sex
All
Age range
from 20 Years
Results posted
No results posted in this snapshot
Countries
Taiwan
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated. 2. Age \> 20 Exclusion Criteria: 1. Unable to complete questionnaires. 2. Prior evidence of brain metastases.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04255628